Objective Health - Specialty Clinical Research of St. Louis
Welcome,         Profile    Billing    Logout  
 0 Trials 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Williams, Sierra
TURBT, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following

Recruiting
3
364
Canada, US
Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
01/28
01/30
NCT04393350: Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma

Active, not recruiting
2
18
US
Lenvatinib, E7080, ER-203492-00, Multi-Kinase Inhibitor E7080, Lenvatinib Mesylate, 4-[3-Chloro-4-(N''-cyclopropylureido)phenoxy]7-methoxyquinoline-6-carboxamide Mesylate, Lenvima, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
Emory University, Merck Sharp & Dohme LLC, National Cancer Institute (NCI)
Kidney Cancer, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
09/24
01/26
NCT05346692: Digital Meditation for Postoperative Pain Control After Abdominal Surgery for Cancer

Completed
1
73
US
Survey Administration, Interview, Text Message-Based Navigation Intervention, Automated Text Message-Based Navigation, Text Message-Based Navigation
Emory University, National Cancer Institute (NCI)
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
07/23
07/23
NCT06674863: Addressing Health Literacy With a Tailored Survivorship Care Plan

Not yet recruiting
N/A
150
US
Educational Intervention, Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational, Interview, Questionnaire Administration, Supportive Care, Supportive Therapy, Symptom Management, Therapy, Supportive
Emory University, National Cancer Institute (NCI), United States Department of Defense
Localized Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
12/29
12/30
NCT03767595: ProACT Post-Approval Study

Recruiting
N/A
145
US
ProACT Adjustable Continence Therapy for Men
Uromedica
Stress Urinary Incontinence
09/25
09/30
Hinds, Peter
TURBT, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following

Recruiting
3
364
Canada, US
Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
01/28
01/30
Narayan, Vikram
TURBT, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following

Recruiting
3
364
Canada, US
Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
01/28
01/30
BLCCR, NCT02660645: Blue Light Cystoscopy With Cysview® Registry

Recruiting
N/A
4400
US
Hexaminolevulinate hydrochloride (HCL), Cysview®, Hexvix®, Karl Storz D-Light C Photodynamic Diagnostic (PDD) system
Photocure, Catalyst Pharmaceutical Research
Bladder Cancer
12/28
12/28
Truesdale, Matthew
TURBT, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following

Recruiting
3
364
Canada, US
Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
01/28
01/30
CORE-008, NCT06567743: Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

Recruiting
2
200
US
Cretostimogene Grenadenorepvec, CG0070
CG Oncology, Inc.
High-Risk Non-Muscle-Invasive Bladder Cancer
03/27
12/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Williams, Sierra
TURBT, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following

Recruiting
3
364
Canada, US
Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
01/28
01/30
NCT04393350: Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma

Active, not recruiting
2
18
US
Lenvatinib, E7080, ER-203492-00, Multi-Kinase Inhibitor E7080, Lenvatinib Mesylate, 4-[3-Chloro-4-(N''-cyclopropylureido)phenoxy]7-methoxyquinoline-6-carboxamide Mesylate, Lenvima, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
Emory University, Merck Sharp & Dohme LLC, National Cancer Institute (NCI)
Kidney Cancer, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
09/24
01/26
NCT05346692: Digital Meditation for Postoperative Pain Control After Abdominal Surgery for Cancer

Completed
1
73
US
Survey Administration, Interview, Text Message-Based Navigation Intervention, Automated Text Message-Based Navigation, Text Message-Based Navigation
Emory University, National Cancer Institute (NCI)
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
07/23
07/23
NCT06674863: Addressing Health Literacy With a Tailored Survivorship Care Plan

Not yet recruiting
N/A
150
US
Educational Intervention, Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational, Interview, Questionnaire Administration, Supportive Care, Supportive Therapy, Symptom Management, Therapy, Supportive
Emory University, National Cancer Institute (NCI), United States Department of Defense
Localized Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
12/29
12/30
NCT03767595: ProACT Post-Approval Study

Recruiting
N/A
145
US
ProACT Adjustable Continence Therapy for Men
Uromedica
Stress Urinary Incontinence
09/25
09/30
Hinds, Peter
TURBT, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following

Recruiting
3
364
Canada, US
Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
01/28
01/30
Narayan, Vikram
TURBT, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following

Recruiting
3
364
Canada, US
Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
01/28
01/30
BLCCR, NCT02660645: Blue Light Cystoscopy With Cysview® Registry

Recruiting
N/A
4400
US
Hexaminolevulinate hydrochloride (HCL), Cysview®, Hexvix®, Karl Storz D-Light C Photodynamic Diagnostic (PDD) system
Photocure, Catalyst Pharmaceutical Research
Bladder Cancer
12/28
12/28
Truesdale, Matthew
TURBT, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following

Recruiting
3
364
Canada, US
Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
01/28
01/30
CORE-008, NCT06567743: Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

Recruiting
2
200
US
Cretostimogene Grenadenorepvec, CG0070
CG Oncology, Inc.
High-Risk Non-Muscle-Invasive Bladder Cancer
03/27
12/27

Download Options